BOSTON, MA and HAMILTON, ONTARIO, February 21, 2018 – Fusion Pharmaceuticals, a biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced it has appointed Marc Schwabish, PhD, as Senior Vice President, Business Development and US Operations. Dr. Schwabish will lead a range of activities including licensing, partnering, commercialization, and financing activities.
Dr. Schwabish joins from Bayer AG where he was Head of US Pharma Business Development and Licensing. He has previous work experience at Eisai, other Pharma and Biotech companies, and Wall Street, following completion of a PhD in Biochemistry.
“This year, Fusion is entering the clinic with our lead program, FPX-01, and we are simultaneously executing an aggressive growth plan through in-licensing and partnership agreements,” said John Valliant, PhD, CEO of Fusion. “Marc’s diverse background and strong BD track record are a perfect match with Fusion’s strategic goals, including the build-out of our US Operations.”
“The vision, technology platform, and rapid progress Fusion has made is extraordinary,” said Dr. Schwabish. “Fusion’s internal discovery and clinical programs and its unique platform technologies enable the company to rapidly develop and evaluate new targeted radiopharmaceuticals. Fusion can use new or existing antibodies – either as a monotherapy or as a combination for a synergistic response. It’s a very exciting time at Fusion and I am honored to join the team.”
About Marc Schwabish
Marc Schwabish was most recently Head of US Pharma Business Development and Licensing at Bayer. He worked across Bayer’s therapeutic areas, focusing on late stage development opportunities, commercialized assets, and innovative partnerships. Prior to Bayer, Marc had both Business Development and Alliance Management responsibilities at Eisai. His deal experience at Eisai covered a range of diseases and stages of assets — from early research technologies through commercialized therapeutics. Marc previously worked in Healthcare Investment Banking at RBS (Leverage Finance and M&A), Pharma Strategy Consulting at Leerink Swann (now Navigant), and other Pharma/Biotech companies (R&D and Product Management). He has closed over 25 transactions across Anti-Infectives, Cardiology, GI, Metabolism, Neurology, Oncology, Thrombosis, and Women’s Healthcare. He holds a Ph.D. in Biochemistry and Molecular Pharmacology from Harvard and a B.S. in Biology from Cornell.
About Fusion Pharmaceuticals, Inc.
Fusion Pharmaceuticals is a biopharmaceutical company located in Hamilton, Ontario, Canada and Boston, MA, focused on becoming the leader in the targeted alpha therapy field. Fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. In addition to its lead program, FPX-01 with a clinical trial planned for 2018, Fusion is expanding its pipeline of products through a proprietary protein discovery platform, in-licensing targeting molecules, and forming new strategic partnerships. For more information, please visit www.fusionpharma.com or contact email@example.com.